Suk-Ouichai Chalairat, Huang Mitchell M, Neill Clayton, Mehta Christopher K, Ross Ashley E, Kundu Shilajit D, Perry Kent T, Pham Duc T, Patel Hiten D
Department of Urology, Feinberg School of Medicine Northwestern University Chicago Illinois USA.
Division of Cardiac Surgery, Department of Surgery, Feinberg School of Medicine Northwestern University Chicago Illinois USA.
BJUI Compass. 2024 Nov 14;6(1):e460. doi: 10.1002/bco2.460. eCollection 2025 Jan.
The objective of this study is to evaluate preoperative factors associated with cardiopulmonary bypass (CPB) utilization and outcomes for patients with renal cell carcinoma (RCC) and tumour thrombus (TT). Radical nephrectomy with thrombectomy is a standard treatment for patients with RCC and associated TT. Morbidity and mortality rates tend to correlate with aggressiveness of tumour and TT level.
Patients undergoing radical nephrectomy with thrombectomy (2006-2023) were retrospectively identified. Inclusion criteria included RCC histology and preoperative imaging available for thrombus-level categorization based on the Mayo Clinic grading system. Logistic regression assessed predictors for utilizing CPB, and Cox regression identified factors associated with survival.
A total of 72 patients with RCC and associated TT were identified. The median age was 67 years. RCC-related symptoms were present in 83%, and 28% had Levels 3 and 4 thrombi. Eleven patients (15.3%) had undergone neoadjuvant therapy, and 81% had clear-cell RCC. CPB was utilized in eight (11.1%) cases. The median tumour size was 10.5 cm. Metastatic disease was greater in the CPB cohort (75% vs. 28%, = 0.008). All cases performed on CPB were Levels 3 and 4 thrombi (100% vs. 19% in the non-CPB group, < 0.001). CPB cases had significantly longer operative time, and hospital stays and rates of Clavien ≥ 3 complications. On multivariate analysis, metastatic disease was a predictor of CPB utilization. Median survival was 74 and 25 months in the non-CPB and CPB cohorts, respectively ( = 0.01). Pulmonary disease and metastatic disease with CPB utilization were significantly associated with worse survival on multivariate analysis.
Surgical extirpation of kidney tumours with associated TT remains the standard of care among patients with locally advanced RCC. CPB can be utilized to increase the feasibility of resection for high-level thrombi. Preoperative planning and cooperation among surgical teams are key given the perioperative morbidity and mortality.
本研究的目的是评估与肾细胞癌(RCC)合并肿瘤血栓(TT)患者体外循环(CPB)使用情况及预后相关的术前因素。根治性肾切除术联合血栓切除术是RCC合并相关TT患者的标准治疗方法。发病率和死亡率往往与肿瘤的侵袭性和TT水平相关。
回顾性确定2006年至2023年期间接受根治性肾切除术联合血栓切除术的患者。纳入标准包括RCC组织学以及基于梅奥诊所分级系统可用于血栓水平分类的术前影像学检查。逻辑回归分析评估使用CPB的预测因素,Cox回归分析确定与生存相关的因素。
共确定72例RCC合并相关TT患者。中位年龄为67岁。83%的患者出现RCC相关症状,28%的患者血栓分级为3级和4级。11例患者(15.3%)接受了新辅助治疗,81%的患者为透明细胞RCC。8例(11.1%)患者使用了CPB。中位肿瘤大小为10.5cm。CPB组的转移疾病情况更为严重(75%对28%,P = 0.008)。所有接受CPB的病例血栓分级均为3级和4级(CPB组为100%,非CPB组为19%,P < 0.001)。CPB病例的手术时间、住院时间显著延长,Clavien≥3级并发症发生率更高。多因素分析显示,转移疾病是使用CPB的预测因素。非CPB组和CPB组的中位生存期分别为74个月和25个月(P = 0.01)。多因素分析显示,使用CPB时的肺部疾病和转移疾病与较差的生存显著相关。
对于局部晚期RCC患者,手术切除合并TT的肾肿瘤仍是标准治疗方法。CPB可用于提高高位血栓切除的可行性。鉴于围手术期的发病率和死亡率,术前规划和手术团队之间的合作至关重要。